

Clinical Policy: Casimersen (Amondys 45)

Reference Number: CP.PHAR.470

Effective Date: 02.25.21

Last Review Date: 02.25

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Casimersen (Amondys 45[®]) is an antisense oligonucleotide.

FDA Approved Indication(s)

Amondys 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

Limitation(s) of use: This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with Amondys 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

All requests reviewed under this policy may **require medical director review**.

It is the policy of health plans affiliated with Centene Corporation[®] that Amondys 45 may be **medically necessary*** when the following criteria are met:

**** Amondys 45 was FDA-approved based on an observed increase in dystrophin in skeletal muscle, but it is unknown if that increase is clinically significant. Continued FDA-approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.***

I. Initial Approval Criteria

A. Duchenne Muscular Dystrophy (must meet all):

1. Diagnosis of DMD with mutation amenable to exon 45 skipping (*see Appendix D*) confirmed by genetic testing;
2. Age \leq 13 years at therapy initiation;
3. Prescribed by or in consultation with a neurologist;
4. Member has all of the following assessed within the last 30 days (a, b, and c):
 - a. Ambulatory function (e.g., ability to walk with or without assistive devices, not wheelchair dependent) with a 6-minute walk test (6MWT) distance \geq 300 m;
 - b. Stable cardiac function with left ventricular ejection fraction (LVEF) \geq 40%;
 - c. Stable pulmonary function with predicted forced vital capacity (FVC) \geq 50%;

5. Inadequate response (as evidenced by a significant decline in 6MWT, LVEF, or FVC) despite adherent use of an oral corticosteroid (e.g., prednisone, Emflaza[®], Agamree[®]) for ≥ 6 months, unless contraindicated or clinically significant adverse effects are experienced;

**Prior authorization is required for Emflaza and Agamree*

6. Amondys 45 is prescribed concurrently with an oral corticosteroid, unless contraindicated or clinically significant adverse effects are experienced;
7. Amondys 45 is not prescribed concurrently with other exon-skipping therapies (e.g., Exondys 51[®], Vyondys 53[®], Viltepso[®]);
8. Member has not previously received gene replacement therapy for DMD (e.g., Elevidys[®]);
9. Dose does not exceed 30 mg/kg per week.

Approval duration: 6 months

II. Continued Therapy

A. Duchenne Muscular Dystrophy (must meet all):

1. Currently receiving medication for DMD with mutation amenable to exon 45 skipping or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by one of the following (a or b):
 - a. All of the following assessed within the last 6 months (i, ii, and iii):
 - i. Ambulatory function (e.g., ability to walk with or without assistive devices, not wheelchair dependent) with a 6MWT distance ≥ 300 m;
 - ii. Stable cardiac function with LVEF $\geq 40\%$;
 - iii. Stable pulmonary function with predicted FVC $\geq 50\%$;
 - b. Member has received this medication via a healthcare insurer without meeting the requirements above (see criterion 2a), and medical record shows improved or stable LVEF and FVC, assessed within the last 6 months;
3. Member has been assessed by a neurologist within the last 6 months;
4. Amondys 45 is prescribed concurrently with an oral corticosteroid, unless contraindicated or clinically significant adverse effects are experienced;
5. Amondys 45 is not prescribed concurrently with other exon-skipping therapies (e.g., Exondys 51, Vyondys 53, Viltepso);
6. Member has not previously received gene replacement therapy for DMD (e.g., Elevidys);
7. If request is for a dose increase, new dose does not exceed 30 mg/kg per week.

Approval duration: 6 months

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

6MWT: 6-minute walk test	ICER: Institute for Clinical and Economic Review
DMD: Duchenne muscular dystrophy	LVEF: left ventricular ejection fraction
FDA: Food and Drug Administration	
FVC: forced vital capacity	

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
prednisone*	0.3-0.75 mg/kg/day or 10 mg/kg/weekend	Based on weight
Emflaza [®] (deflazacort)	0.9 mg/kg/day orally once daily	Based on weight
Agamree [®] (vamorolone)	6 mg/kg/day PO QD (up to a maximum of 300 mg/day) <ul style="list-style-type: none"> • If member has mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment: 2 mg/kg/day PO QD (up to a maximum of 100 mg/day) • If co-administered with strong CYP3A4 inhibitors (e.g., itraconazole): 4 mg/kg/day PO QD (up to a maximum of 200 mg/day) 	See regimen

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

**Off-label*

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): serious hypersensitivity to casimersen or to any of the inactive ingredients in Amondys 54
- Boxed warning(s): none reported

Appendix D: General Information

- Common mutations amenable to exon 45 skipping include: 7-44, 12-44, 18-44, 44, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-57, 46-59, 46-60, 46-67, 46-69, 46-75, 46-78.
- Corticosteroids are routinely used in DMD management with established efficacy in slowing decline of muscle strength and function (including motor, respiratory, and cardiac). They are recommended for all DMD patients per the American Academy of Neurology (AAN) and DMD Care Considerations Working Group; in addition, the AAN guidelines have been endorsed by the American Academy of Pediatrics, the American Association of Neuromuscular & Electrodiagnostic Medicine, and the Child Neurology Society.

- The DMD Care Considerations Working Group guidelines, which were updated in 2018, continue to recommend corticosteroids as the mainstay of therapy.
- In an evidence report published August 2019, the Institute for Clinical and Economic Review (ICER) states that current evidence is insufficient to conclude that other exon-skipping therapies (Exondys 51, Vyondys 53) have net clinical benefit when added to corticosteroids and supportive care versus corticosteroids and supportive care alone.
- Prednisone is the corticosteroid with the most available evidence. A second corticosteroid commonly used is deflazacort, which was FDA approved for DMD in February 2017. On October 2023, a third corticosteroid, vamorolone, was approved by the FDA for DMD.
- The inclusion criteria for the ESSENCE study (NCT02500381) used to support the FDA approval of casimersen enrolled male patients age 7-13 years old with a mean 6MWT distance of 300 m or more at screening and baseline visits and stable pulmonary function with %pFVC \geq 50%.
- Having an LVEF below 40% may indicate presence of cardiomyopathy or heart failure.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
DMD	30 mg/kg IV once weekly	30 mg/kg/week

VI. Product Availability

Single-dose vial: 100 mg/2 mL

VII. References

1. Amondys 45 Prescribing Information. Cambridge, MA: Sarepta Therapeutics, Inc.; July 2024. Available at: [https://amondys45.com/Amondys45_\(casimersen\)_Prescribing_Information.pdf](https://amondys45.com/Amondys45_(casimersen)_Prescribing_Information.pdf). Accessed October 25, 2024.
2. ClinicalTrials.gov. Study of SRP-4045 and SRP-4053 in DMD patients (ESSENCE). Available at: <https://clinicaltrials.gov/ct2/show/NCT02500381>. Accessed October 31, 2024.
3. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. 2018; 17: 251-267.
4. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy. *Neurology*. 2016; 86: 465-472. Reaffirmed on January 22, 2022.
5. Institute for Clinical and Economic Review. Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: Effectiveness and value. Published August 15, 2019. Available at: https://icer.org/wp-content/uploads/2020/10/Corrected_ICER_DMD-Final-Report_042222.pdf. Accessed October 31, 2024.
6. CureDuchenne. Exon skipping. Available at: <https://www.cureduchenne.org/cure/exon-skipping>. Accessed October 31, 2024.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1426	Injection, casimersen, 10 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2021 annual review: drug is now FDA approved; added option for continuation of therapy for patients who have been receiving the medication through another healthcare insurer and/or has been responding positively to therapy with stable disease; modified time frame for positive response parameters from within the last 30 days to within the last 6 months; added requirement for neurologist assessment within the last 6 months; LVEF requirement revised from > to ≥ 40%; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated; added disclaimer under Policy/Criteria “All requests reviewed under this policy require medical director review.”	02.26.21	05.21
1Q 2022 annual review: no significant changes; updated Coding Implications section; added that the review “may” require medical director review; references reviewed and updated.	09.14.21	02.22
1Q 2023 annual review: no significant changes; updated Section III to match template; updated HCPCS code; references reviewed and updated.	11.07.22	02.23
1Q 2024 annual review: added criteria, member has not previously received gene replacement therapy for DMD (e.g., Elevidys); added Agamree to list of corticosteroids in Appendix B; references reviewed and updated.	10.13.23	02.24
1Q 2025 annual review: no significant changes; updated Appendix C with new contraindication per PI; references reviewed and updated.	10.31.24	02.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health

plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise

published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.